Insight Molecular Diagnostics Inc. filed a Form 8-K on November 18, 2026, disclosing the entry into an underwriting agreement on November 17, 2026, for an underwritten public offering expected to generate approximately $15.0 million in aggregate gross proceeds.

Key Highlights

  • Offering size: Aggregate gross proceeds are expected to be approximately $15.0 million, before deducting underwriting discounts, commissions, and estimated expenses payable by the company.
  • Securities offered: 8,296,429 shares of common stock and pre-funded warrants to purchase up to 275,000 shares of common stock.
  • Offering prices: $1.75 per share and $1.7499 per pre-funded warrant, with an exercise price of $0.0001 per share for the pre-funded warrants.
  • Overallotment option: The underwriter received a 30-day option to purchase up to an additional 1,285,714 shares at the public offering price, net of underwriting discounts and commissions.
  • Use of proceeds: The company disclosed it intends to use net proceeds for working capital and general corporate purposes.
  • Lock-up period: The company agreed not to dispose of, or announce the offering of, shares or convertible securities for 90 days following the date of the underwriting agreement, subject to certain exceptions.

Insight Molecular Diagnostics Underwritten Offering Terms and Structure

According to the filing, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) entered into an underwriting agreement on November 17, 2026, with Lake Street Capital Markets, LLC as sole underwriter. The offering consists of two types of securities: 8,296,429 shares of the company's common stock, no par value per share, and pre-funded warrants to purchase up to 275,000 shares of common stock. The public offering price was set at $1.75 per share and $1.7499 per pre-funded warrant. The offering was expected to close on or about November 18, 2026, subject to the satisfaction or waiver of customary closing conditions.

The filing states that all securities in the offering are being sold by the company, with expected aggregate gross proceeds of approximately $15.0 million before deductions. Each pre-funded warrant carries an exercise price of $0.0001 per share, is immediately exercisable upon issuance, and may be exercised at any time until exercised in full. The filing notes that a holder may not exercise any portion of its pre-funded warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise.

The offering is being made pursuant to the company's registration statement on Form S-3 (File No. 333-281159), filed with the SEC on August 1, 2024, and declared effective on August 7, 2024. The filing also discloses that the company issued press releases on November 16, 2026, announcing the launch of the offering, and on November 17, 2026, announcing the pricing. The underwriting agreement was signed on behalf of the company by Peter Hong, Vice President and General Counsel.

What Was Disclosed

Insight Molecular Diagnostics filed an 8-K reporting entry into an underwriting agreement for a public offering of shares and pre-funded warrants, with expected gross proceeds of approximately $15.0 million, underwritten by Lake Street Capital Markets, LLC, with an expected closing date of on or about November 18, 2026.